SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : HEB, Hemispherx Biopharma (AMEX)NEW
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (178)3/3/1998 11:55:00 AM
From: MarcG  Read Replies (1) of 857
 
Hi Linda, I guess you misinterpreted the word "discounting" in relationship to stock prices. A stock can go up and be discounting favorable events. HEB should soon discount the possibilities
of a U.S. based diagnostic test, the Olsten/HEB distribution agreement, the scaling up of Ampligen production at the SAB plant, and the possible FDA approval for CFS trial expansion, by rewarding shareholders with a higher stock price. At these levels ($3-4), IMO, none of the above factors are discounted in the stock price. ( :
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News